These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 21041299

  • 21. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis.
    Slungaard A, Key NS.
    J Biol Chem; 1994 Oct 14; 269(41):25549-56. PubMed ID: 7523387
    [Abstract] [Full Text] [Related]

  • 22. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
    Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D, Semeraro N.
    Thromb Haemost; 2002 Aug 14; 88(2):282-7. PubMed ID: 12195701
    [Abstract] [Full Text] [Related]

  • 23. The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.
    Wu C, Kim PY, Manuel R, Seto M, Whitlow M, Nagashima M, Morser J, Gils A, Declerck P, Nesheim ME.
    J Biol Chem; 2009 Mar 13; 284(11):7059-67. PubMed ID: 19074424
    [Abstract] [Full Text] [Related]

  • 24. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
    Boffa MB, Wang W, Bajzar L, Nesheim ME.
    J Biol Chem; 1998 Jan 23; 273(4):2127-35. PubMed ID: 9442053
    [Abstract] [Full Text] [Related]

  • 25. Modulation of TAFI function through different pathways--implications for the development of TAFI inhibitors.
    Gils A, Ceresa E, Macovei AM, Marx PF, Peeters M, Compernolle G, Declerck PJ.
    J Thromb Haemost; 2005 Dec 23; 3(12):2745-53. PubMed ID: 16359512
    [Abstract] [Full Text] [Related]

  • 26. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
    Zhou X, Declerck PJ.
    J Thromb Haemost; 2015 Jun 23; 13(6):1084-9. PubMed ID: 25773535
    [Abstract] [Full Text] [Related]

  • 27. Angiopoietins bind thrombomodulin and inhibit its function as a thrombin cofactor.
    Daly C, Qian X, Castanaro C, Pasnikowski E, Jiang X, Thomson BR, Quaggin SE, Papadopoulos N, Wei Y, Rudge JS, Thurston G, Yancopoulos GD, Davis S.
    Sci Rep; 2018 Jan 11; 8(1):505. PubMed ID: 29323190
    [Abstract] [Full Text] [Related]

  • 28. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
    Ammollo CT, Semeraro F, Vitulli A, Dirienzo L, Mezzasoma AM, Semeraro N, Gresele P, Colucci M.
    Haemophilia; 2020 Jul 11; 26(4):e151-e160. PubMed ID: 32325538
    [Abstract] [Full Text] [Related]

  • 29. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
    Bazzi ZA, Lanoue D, El-Youssef M, Romagnuolo R, Tubman J, Cavallo-Medved D, Porter LA, Boffa MB.
    BMC Cancer; 2016 May 24; 16():328. PubMed ID: 27221823
    [Abstract] [Full Text] [Related]

  • 30. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains.
    Hall SW, Nagashima M, Zhao L, Morser J, Leung LL.
    J Biol Chem; 1999 Sep 03; 274(36):25510-6. PubMed ID: 10464282
    [Abstract] [Full Text] [Related]

  • 31. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin.
    Mosnier LO, Meijers JC, Bouma BN.
    Thromb Haemost; 2001 Jan 03; 85(1):5-11. PubMed ID: 11204587
    [Abstract] [Full Text] [Related]

  • 32. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
    Mosnier LO, Meijers JC, Bouma BN.
    Thromb Haemost; 2001 Oct 03; 86(4):1040-6. PubMed ID: 11686322
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F, Carrieri C, Galasso R, Scaraggi FA, Di Serio F, Woodhams B, Semeraro N, Colucci M.
    J Thromb Haemost; 2013 Feb 03; 11(2):315-24. PubMed ID: 23256818
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time.
    Urano T, Sano Y, Suzuki Y, Okada M, Sano H, Honkura N, Morooka N, Doi M, Suzuki Y.
    Res Pract Thromb Haemost; 2024 May 03; 8(4):102463. PubMed ID: 39026660
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis.
    Dai L, Mitchell M, Savidge G, Alhaq A.
    J Thromb Haemost; 2004 Dec 03; 2(12):2200-4. PubMed ID: 15613027
    [Abstract] [Full Text] [Related]

  • 38. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
    Foley JH, Nesheim ME, Rivard GE, Brummel-Ziedins KE.
    Haemophilia; 2012 May 03; 18(3):e316-22. PubMed ID: 21933309
    [Abstract] [Full Text] [Related]

  • 39. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
    Binette TM, Taylor FB, Peer G, Bajzar L.
    Blood; 2007 Nov 01; 110(9):3168-75. PubMed ID: 17644733
    [Abstract] [Full Text] [Related]

  • 40. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
    Nielsen VG, Kirklin JK.
    Blood Coagul Fibrinolysis; 2008 Dec 01; 19(8):793-800. PubMed ID: 19002046
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.